Xeltis B.V.

Xeltis is a clinical-stage medical device company pioneering a restorative approach in cardiovascular therapy. RestoreX™, Xeltis technology platform, is the world’s first polymer-based technology designed to enable natural restoration of cardiovascular function, through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis is currently investigating applications of its innovative approach to restore heart valves and small diameter blood vessels.

Over 25 patients implanted:

• Restorative small diameter vascular applications, including Coronary Artery Bypass Grafts (CABG) are showing promising results in preclinical trials.
• The first few patients receiving Xeltis pediatric vascular grafts have now reached their 5-year follow-up.
• Xeltis restorative heart valves have been in trials for years, including two clinical trials in EU, Asia and in the USA.